266 related articles for article (PubMed ID: 23649995)
1. Formulation and in vivo evaluation of orally disintegrating tablets of clozapine/hydroxypropyl-β-cyclodextrin inclusion complexes.
Zeng F; Wang L; Zhang W; Shi K; Zong L
AAPS PharmSciTech; 2013 Jun; 14(2):854-60. PubMed ID: 23649995
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes.
Desai C; Prabhakar B
Drug Dev Ind Pharm; 2015; 41(10):1589-607. PubMed ID: 25350555
[TBL] [Abstract][Full Text] [Related]
3. Development of orally disintegrating tablets of Perphenazine/hydroxypropyl-β-cyclodextrin inclusion complex.
Wang L; Zeng F; Zong L
Pharm Dev Technol; 2013; 18(5):1101-10. PubMed ID: 22759202
[TBL] [Abstract][Full Text] [Related]
4. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
5. Formulation and evaluation of clozapine orally disintegrating tablets prepared by direct compression.
Olmez SS; Vural I; Sahin S; Ertugrul A; Capan Y
Pharmazie; 2013 Feb; 68(2):110-6. PubMed ID: 23469682
[TBL] [Abstract][Full Text] [Related]
6. Manufacturing and Assessing the New Orally Disintegrating Tablets, Containing Nimodipine-hydroxypropyl-β-cyclodextrin and Nimodipine-methyl-β-cyclodextrin Inclusion Complexes.
Novac M; Musuc AM; Ozon EA; Sarbu I; Mitu MA; Rusu A; Gheorghe D; Petrescu S; Atkinson I; Lupuliasa D
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335371
[TBL] [Abstract][Full Text] [Related]
7. Formulation and development of extended-release micro particulate drug delivery system of solubilized rifaximin.
Karanje RV; Bhavsar YV; Jahagirdar KH; Bhise KS
AAPS PharmSciTech; 2013 Jun; 14(2):639-48. PubMed ID: 23516110
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes.
Patel SG; Rajput SJ
AAPS PharmSciTech; 2009; 10(2):660-9. PubMed ID: 19459053
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-beta-cyclodextrin.
Nie S; Fan X; Peng Y; Yang X; Wang C; Pan W
Arch Pharm Res; 2007 Aug; 30(8):991-1001. PubMed ID: 17879753
[TBL] [Abstract][Full Text] [Related]
10. Ternary complexation of carvedilol, beta-cyclodextrin and citric acid for mouth-dissolving tablet formulation.
Pokharkar V; Khanna A; Venkatpurwar V; Dhar S; Mandpe L
Acta Pharm; 2009 Jun; 59(2):121-32. PubMed ID: 19564138
[TBL] [Abstract][Full Text] [Related]
11. Formulation of cyclodextrin inclusion complex-based orally disintegrating tablet of eslicarbazepine acetate for improved oral bioavailability.
Desai S; Poddar A; Sawant K
Mater Sci Eng C Mater Biol Appl; 2016 Jan; 58():826-34. PubMed ID: 26478377
[TBL] [Abstract][Full Text] [Related]
12. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
Zhang X; Zhang T; Lan Y; Wu B; Shi Z
AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
[TBL] [Abstract][Full Text] [Related]
13. Improvement of aripiprazole solubility by complexation with (2-hydroxy)propyl-β-cyclodextrin using spray drying technique.
Mihajlovic T; Kachrimanis K; Graovac A; Djuric Z; Ibric S
AAPS PharmSciTech; 2012 Jun; 13(2):623-31. PubMed ID: 22535520
[TBL] [Abstract][Full Text] [Related]
14. The physicochemical characteristics and bioavailability of indomethacin from beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, and hydroxypropyl-beta-cyclodextrin complexes.
Jambhekar S; Casella R; Maher T
Int J Pharm; 2004 Feb; 270(1-2):149-66. PubMed ID: 14726131
[TBL] [Abstract][Full Text] [Related]
15. Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies.
Sherje AP; Kulkarni V; Murahari M; Nayak UY; Bhat P; Suvarna V; Dravyakar B
Mol Pharm; 2017 Apr; 14(4):1231-1242. PubMed ID: 28248111
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of orally disintegrating tablets of perphenazine/hydroxypropyl-beta-cyclodextrin inclusion complex in rabbits.
Wang L; Xiao YY; Chen ML; Zeng F; Zong L
Pharmazie; 2013 Oct; 68(10):800-4. PubMed ID: 24273883
[TBL] [Abstract][Full Text] [Related]
17. Influence of hydroxypropyl-beta-cyclodextrin complexation on piroxicam release from buccoadhesive tablets.
Jug M; Bećirević-Laćan M
Eur J Pharm Sci; 2004 Feb; 21(2-3):251-60. PubMed ID: 14757497
[TBL] [Abstract][Full Text] [Related]
18. Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-beta-cyclodextrin complex.
Lv HX; Zhang ZH; Hui-Jiang ; Waddad AY; Zhou JP
Pharmazie; 2012 Jan; 67(1):46-53. PubMed ID: 22393830
[TBL] [Abstract][Full Text] [Related]
19. Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes.
Cirri M; Rangoni C; Maestrelli F; Corti G; Mura P
Drug Dev Ind Pharm; 2005 Aug; 31(7):697-707. PubMed ID: 16207617
[TBL] [Abstract][Full Text] [Related]
20. Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects.
Lima BDS; Campos CA; da Silva Santos ACR; Santos VCN; Trindade GDGG; Shanmugam S; Pereira EWM; Marreto RN; Duarte MC; Almeida JRGDS; Quintans JSS; Quintans LJ; Araújo AAS
Food Chem Toxicol; 2019 Apr; 126():15-24. PubMed ID: 30738132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
